RxDoctor Payments Data

Bryce Ayers, MD

Internal Medicine · Washington, MONPI 1689610446

Payments from drug & device makers

$1,127in general payments, 2019–2025

Across 63 payments — averaging $17.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$521
  • Johnson & Johnson$121
  • GSK$70
  • Amgen$66
  • Novo Nordisk$55
  • Lundbeck LLC$39
  • plus $254 from 11 others

What the payments were for

  • Food & beverage$1,08897%
  • Education$393%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,127 in reported general payments places this provider in the 70th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$109,792
Medicare patients
298
Services billed
1,579

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide297$383,861
EliquisApixaban338$306,504
JardianceEmpagliflozin263$281,881
XareltoRivaroxaban190$172,829
MounjaroTirzepatide129$145,527
FarxigaDapagliflozin Propanediol186$134,843
TrulicityDulaglutide76$109,261
Repatha SureclickEvolocumab91$80,913
Trelegy ElliptaFluticasone/Umeclidin/Vilanter102$80,896
MyrbetriqMirabegron86$62,816
AbrysvoRsv Vacc, Pref A And Pref B/Pf162$42,259
Tresiba Flextouch U-200Insulin Degludec38$41,647
Tresiba Flextouch U-100Insulin Degludec79$36,430
LinzessLinaclotide38$26,830
ArexvyRsvpref3 Antigen/As01e/Pf99$24,926

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$55$406,450310 claims
PfizerEliquis, Abrysvo, Premarin$29$356,988514 claims
Lilly USA, LLCMounjaro, Trulicity$15$254,788205 claims
Johnson & JohnsonXarelto, Invokana$121$187,223201 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Brilinta$36$185,193272 claims
GSKTrelegy Ellipta, Arexvy, Breo Ellipta$70$118,303232 claims
AbbVieLinzess$521$26,83038 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Washington

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →